Article Text

Download PDFPDF
Immunomodulation in Endometrial Cancer
  1. Nicole Brooks and
  2. Dodie S. Pouniotis, PhD
  1. School of Medical Sciences, RMIT University, Bundoora, Victoria, Australia.
  1. Address correspondence and reprint requests to Dodie S. Pouniotis, PhD, School of Medical Sciences, RMIT University, PO Box 71, Bundoora, Victoria, Australia, 3083. E-mail: dodie.pouniotis{at}


Endometrial cancer is the most frequent gynecological cancer and the fourth most common cancer in women in the developed world. Over the last decade, immunotherapy has been the focus of intense investigation as a form of cancer treatment whereby the treatment initiates a host immune response ultimately eradicating the tumor. It has been suggested that in endometrial cancer and many other forms of cancer, immunosuppression poses a significant obstacle at inducing antitumor immunity by immunotherapy. This review will look at the different studies that have identified immunomodulation of T cells, cytokines and macrophages, and regulation of apoptotic and angiogenic factors in endometrial cancer patients that may contribute to the inefficiency of immunotherapy.

  • Endometrial cancer
  • Immunomodulation
  • Immunotherapy

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.